Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy
Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy(334 views) Pace L, Klain M, Soricelli A, Albanese C, Salvatore B, Storto G, Salvatore M
Keywords: Iodine 131, Adult, Aged, Article, Cancer Patient, Cancer Recurrence, Controlled Study, Female, Follicular Carcinoma, Follow Up, Human, Major Clinical Study, Medical Assessment, Papillary Carcinoma, Retrospective Study, Thyroglobulin Blood Level, Thyroid Carcinoma, Thyroidectomy, Treatment Outcome, Adenocarcinoma, 80 And Over, Disease Progression, Iodine Radioisotopes, Middle Aged, Thyroid Neoplasms, Thyroxine,
Affiliations: *** IBB - CNR ***
Dipartimento di Scienze Biomorfologiche e Funzionali, Università degli Studi di Napoli Federico II, Napoli, Italy
Istituto di Biostrutture e Bioimmagini, C.N.R., Napoli, Italy
References: Ozata, M., Suzuki, S., Myamoto, T., Liu, R.T., Fierro-Renoy, F., Degrot, L.J., Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer (1994) J Clin Endocrinol Metab, 79, pp. 98-10
Duren, M., Siperstein, A.E., Sheen, W., Duh, Q.Y., Morita, E., Clark, O.H., Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high and low-risk patients (1999) Surgery, 126, pp. 13-19
Pacini, F., Pinchera, A., Serum and tissue thyroglobulin measurements: Clinical applications in thyroid disease (1999) Biochimie, 81, pp. 463-467
Mazzaferri, E.L., Robbins, R.J., Spencer, C.A., Braverman, L.E., Pacini, F., Wartofsky, L., A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma (2003) J Clin Endocrinol Metab, 88, pp. 1433-1441
Pacini, F., Capezzone, M., Elisei, R., Ceccarelli, C., Tadei, D., Pinchera, A., Diagnostic 131-1 whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment (2002) J Clin Endocrinol Metab, 87, pp. 1499-1501
Lind, P., I-131 whole body scintigraphy in thyroid cancer patients (1999) Q J Nucl Med, 43, pp. 188-194
Lind, P., Should high hTg levels in the absence of iodine uptake be treated? for (2003) Eur J Nucl Med Mol Imaging, 30, pp. 157-160
Schlumberger, M., Tubiana, M., De Vathaire, F., Hill, C., Gardet, P., Travagli, J.P., Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma (1986) J Clin Endocrinol Metab, 63, pp. 960-967
Nemec, J., Rohling, S., Zamrazil, V., Pohunkova, D., Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancer (1979) J Nucl Med, 20, pp. 92-97
Pacini, F., Lari, R., Mazzeo, S., Grasso, L., Taddei, D., Pinchera, A., Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer (1985) Clin Endocrinol, 23, pp. 405-411. , Oxf
Schlumberger, M., Arcangioli, O., Piekarski, J.D., Tubiana, M., Parmentier, C., Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-ray (1988) J Nucl Med, 29, pp. 1790-1794
Sherman, S.I., Tielens, E.T., Sostre, S., Wharam Jr., M.D., Ladenson, P.W., Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma (1994) J Clin Endocrinol Metab, 78, pp. 629-634
Reynolds, J.C., Percent 131-I uptake and post-therapy 131-I scans: Their role in the management of thyroid cancer (1997) Thyroid, 7, pp. 281-284
Schlumberger, M., Use of radioactive iodine in patients with papillary and follicular thyroid cancer: Toward a selective approach (1988) J Clin Endocrinol Metab, 83, pp. 4201-4203
Bierman, M., Schober, O., Should high hTg levels in the absence of iodine uptake be treated? Against (2003) Eur J Nucl Med Mol Imaging, 30, pp. 160-163
Pacini, F., Agate, L., Elisei, R., Capezzone, M., Ceccarelli, C., Lippi, F., Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: Comparison of patients treated with high 131-I activities versus untreated patients (2001) J Clin Endocrinol Metab, 86, pp. 4092-4097
Fatourechi, V., Hay, I.D., Javedan, H., Wiseman, G.A., Mullan, B.P., Gorman, C.A., Lack of impact of radioiodine therapy in Tg positive, diagnostic whole body scan-negative patients with follicular cell-derived thyroid cancer (2002) J Clin Endocrinol Metab, 87, pp. 1521-1526
Pineda, J.D., Lee, T., Ain, K., Reynolds, J.C., Robbins, J., Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan (1995) J Clin Endocrinol Metab, 80, pp. 1488-1492
Koh, J.M., Es, K., Ryu, J.S., Hong, S.J., Kim, W.B., Shong, Y.K., Effects of therapeutic doses of 131-I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131-I whole body scan: Comparative study (2003) Clin Endocrinol, 58, pp. 421-427
Venkataraman, G.M., Yatin, M., Ain, K.B., Cloning of the human sodium-iodine symporter promoter and characterization in a different human thyroid cell line (1998) Thyroid, 8, pp. 63-69
Lazar, V., Bidart, J.M., Caillou, B., Mahe, C., Lacroix, L., Filetti, S., Expression of the Na+7I - Symporter gene in human thyroid tumors: A comparison study with other thyroid-specific genes (1999) J Clin Endocrinol Metab, 84, pp. 3228-3234
Arturi, F., Russo, D., Schlumberger, M., Du Villard, J.A., Caillou, B., Vigneri, P., Iodide symporter gene expression in human thyroid tumors (1998) J Clin Endocrinol Metab, 83, pp. 2493-2496
Min, J.J., Chung, J.K., Lee, Y.J., Jeong, J.M., Lee, D.S., Jang, J.J., Relationship between expression of the sodium/iodide symporter and 131-I uptake in recurrent lesions of differentiated thyroid carcinoma (2001) Eur J Nucl Med, 28, pp. 639-645
Robbins, R.J., Schlumberger, M.J., The evolving role of 131-I for the treatment of differentiated thyroid carcinoma (2005) J Nucl Med, 46, pp. 28S-37S
Schmutzler, C., Regulation of the sodium/iodide symporter by retinoids: A review (2001) Exp Clin Endocrinol Diabetes, 109, pp. 41-44
Pacini, F., Follow-up of differentiated thyroid cancer (2002) Eur J Nucl Med Mol Imaging, 20, pp. S492-6
Stokkel, M.P.M., Verkooijen, R.B., Smit, J.W.A., Indium-111 octreotide scintigraphy for the detection of non-functioning metastasis from differentiated thyroid cancer: Diagnostic and prognostic value (2004) Eur J Nucl Med Mol Imaging, 31, pp. 950-957
Gabriel, M., Froehlich, F., Decristoforo, C., Ensinger, C., Donnemiller, E., Von Guggenberg, E., 99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans (2004) Eur J Nucl Med Mol Imaging, 31, pp. 330-341
Hooft, L., Hoekstra, O.S., Deville, W., Lips, P., Teule, C.J.J., Boers, M., Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer (2001) J Clin Endocrinol Metab, 86, pp. 3779-3786
Schluter, B., Bohuslavizki, K.H., Beyer, W., Plotkin, M., Buchert, R., Clausen, M., Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131-I scan (2001) J Nucl Med, 42, pp. 71-76
Helal, B.O., Merlot, P., Toubert, M.E., Franc, B., Schvartz, C., Gauthier-Koelesnikov, H., Clinical impact of 18-F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131-I scanning results after therapy (2001) J Nucl Med, 42, pp. 1464-1469
Alnafisi, N.S., Driedger, A.A., Coates, G., Moote, D.J., Raphael, S.J., FDG PET of recurrent or metastatic 131-I-negative papillary thyroid carcinoma (2000) J Nucl Med, 41, pp. 1010-1015
Wang, W., Larson, S.M., Fazzari, M., Tickoo, S.K., Kolbert, K., Sgouros, G., Prognostic value of (18F)fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer (2000) J Clin Endocrinol Metab, 85, pp. 1107-1113
Mazzaferri, E. L., Robbins, R. J., Spencer, C. A., Braverman, L. E., Pacini, F., Wartofsky, L., A consensus report of the role of serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma (2003) J Clin Endocrinol Metab, 88, pp. 1433-1441
Sherman, S. I., Tielens, E. T., Sostre, S., Wharam Jr., M. D., Ladenson, P. W., Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma (1994) J Clin Endocrinol Metab, 78, pp. 629-634
Reynolds, J. C., Percent 131-I uptake and post-therapy 131-I scans: Their role in the management of thyroid cancer (1997) Thyroid, 7, pp. 281-284
Pineda, J. D., Lee, T., Ain, K., Reynolds, J. C., Robbins, J., Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan (1995) J Clin Endocrinol Metab, 80, pp. 1488-1492
Koh, J. M., Es, K., Ryu, J. S., Hong, S. J., Kim, W. B., Shong, Y. K., Effects of therapeutic doses of 131-I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131-I whole body scan: Comparative study (2003) Clin Endocrinol, 58, pp. 421-427
Venkataraman, G. M., Yatin, M., Ain, K. B., Cloning of the human sodium-iodine symporter promoter and characterization in a different human thyroid cell line (1998) Thyroid, 8, pp. 63-69
Min, J. J., Chung, J. K., Lee, Y. J., Jeong, J. M., Lee, D. S., Jang, J. J., Relationship between expression of the sodium/iodide symporter and 131-I uptake in recurrent lesions of differentiated thyroid carcinoma (2001) Eur J Nucl Med, 28, pp. 639-645
Robbins, R. J., Schlumberger, M. J., The evolving role of 131-I for the treatment of differentiated thyroid carcinoma (2005) J Nucl Med, 46, pp. 28S-37S
Stokkel, M. P. M., Verkooijen, R. B., Smit, J. W. A., Indium-111 octreotide scintigraphy for the detection of non-functioning metastasis from differentiated thyroid cancer: Diagnostic and prognostic value (2004) Eur J Nucl Med Mol Imaging, 31, pp. 950-957
Helal, B. O., Merlot, P., Toubert, M. E., Franc, B., Schvartz, C., Gauthier-Koelesnikov, H., Clinical impact of 18-F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131-I scanning results after therapy (2001) J Nucl Med, 42, pp. 1464-1469
Alnafisi, N. S., Driedger, A. A., Coates, G., Moote, D. J., Raphael, S. J., FDG PET of recurrent or metastatic 131-I-negative papillary thyroid carcinoma (2000) J Nucl Med, 41, pp. 1010-1015
Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy
Purpose: The aim of this study was to evaluate the usefulness of high-dose 131I therapy administered only on the basis of raised serum Tg levels. Methods: Among patients treated with total or near-total thyroidectomy and 131I ablation, 76 (54 women and 22 men) with differentiated thyroid cancer (41 with follicular and 35 with papillary cancer) showed a detectable (i.e. >1.5 ng/ml) serum Tg level on L-thyroxine therapy during follow-up and were included in the study. In these patients, a further 131I therapy was scheduled (range 3.7-9.25 GBq, mean 6.087±1.705). Five to seven days after this radioiodine therapy, patients underwent 131I post-therapy whole-body scan (131I t-WBS). The serum Tg value at 12 months after 131I therapy was evaluated as an indicator of short-term response to radioiodine. Results: At evaluation after 12 months, 21 (27.6%) of the 76 patients had a Tg value ≤1.5 ng/ml, 12 (15.8%) showed a Tg decrease of at least 50%, 22 (29%) had only a minor decrease in Tg (
Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy
Short Term Outcome of Differentiated Thyroid Cancer Patients with Detectable Serum Thyroglobulin after Initial Treatment Receiving a Second 131-IODINE Therapy
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(284 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(349 views) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 ViewExport to BibTeXExport to EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(849 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote
Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, Von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, De Jong M * The EEE project(449 views) Proc Int Cosm Ray Conf Icrc Universidad Nacional Autonoma De Mexico, 2007; 5(HEPART2): 977-980. Impact Factor:0 ViewExport to BibTeXExport to EndNote
Vitiello M, Finamore E, Falanga A, Raieta K, Cantisani M, Galdiero F, Pedone C, Galdiero M, Galdiero S * Fusion in Coq(479 views) Lecture Notes In Computer Science (ISSN: 0302-9743, 0302-974335404636319783540463634, 0302-974335402975459783540297543), 2001; 2178LNCS: 583-596. Impact Factor:0.415 ViewExport to BibTeXExport to EndNote